Christian Riedel
Hi, everybody. Welcome to this PTX Investor Briefing. While people settle in, I’ll just provide the disclaimer for the session quickly.
The presentations that we host are suitable for self-directed investors who have the experience and capabilities to make their own informed decisions. Any information contained in today’s presentation is general nature does not consider your personal circumstances to consider for yourself and is appropriate for you. The information we’re giving you is for educational purposes only. Past performance not a reliable indicator of future performance.
Great. With that, let’s kick off the session. I’m Christian Riedel, Executive Director at Reach. I’ll be hosting the session today. Many might know me from the recent capital raise where James and I did just quite a few of these webcasts to both shareholders and potential new investors. James is here with me, James McDonnell, CEO of Prescient. And today’s update is off the back of their recent 4C announcement, which included an update on the Phase IIa study for cancer treatment of PTX-100 with 7 clinical sites now open in Australia and the U.S.
How we’re going to run the session is I’ll first ask James a few questions about the recent news, recent releases, and then I’ll let him run through the deck. It will be, I think, a combination of, the normal deck and also the AGM presentation and reflecting some of these new releases. And then we’re going to follow up with some Q&A to catch anything we haven’t covered and also open the floor to the audience here to get an update. We expect the session to
